Related Experiment Videos
Vaccination against Leishmania infections.
1Institute of Biochemistry, Ch. des Boveresses 155, CH-1066 Epalinges, Switzerland. Jacques.Mauel@ib.unil.ch
Current Drug Targets. Immune, Endocrine and Metabolic Disorders
|December 13, 2002
Summary
Developing effective vaccines against leishmaniasis, a growing global infectious disease, is feasible. Research explores various approaches, but a definitive vaccination strategy remains elusive.
Area of Science:
- Immunology
- Parasitology
- Vaccinology
Background:
- Leishmaniasis is a significant protozoan parasitic disease affecting millions globally, with increasing incidence.
- The disease presents in cutaneous, mucocutaneous, and visceral forms, with the latter two being fatal without treatment.
- Immunity following recovery suggests vaccination potential.
Purpose of the Study:
- To review the immunological aspects of Leishmania infections and recovery mechanisms.
- To outline experimental vaccination strategies for leishmaniasis in humans and animals.
- To assess the feasibility and challenges of developing a leishmaniasis vaccine.
Main Methods:
- Review of existing literature on leishmaniasis immunology and vaccine development.
- Analysis of various vaccination approaches: live/attenuated organisms, parasite extracts, purified proteins.
- Inclusion of novel methods: DNA vaccination, vector-based vaccines, and anti-vector saliva immunity.
Main Results:
- Recovery from leishmaniasis confers solid immunity, supporting vaccine development.
- Numerous experimental vaccination strategies have shown promise in preclinical and clinical studies.
- Despite progress, a universally accepted optimal vaccination approach is yet to be established.
Conclusions:
- Vaccination against leishmaniasis is scientifically plausible.
- Diverse experimental vaccine candidates and technologies are under investigation.
- Further research is needed to achieve a consensus on the most effective leishmaniasis vaccine strategy.